Two Type 2 Diabetes Drugs Linked to Higher Risk of Heart Disease

Are second-line antidiabetic medications (ADMs) associated with cardiovascular events among insured adult patients with type 2 diabetes who are initiating second-line therapy?

This cohort study of 132 737 adults with type 2 diabetes found that glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, and sodium-glucose cotransporter 2 inhibitors were associated with similar cardiovascular outcomes. Sulfonylureas and basal insulin were associated with comparatively higher cardiovascular risk.

MClinicians may consider prescribing newer ADM classes more routinely after metformin rather than sulfonylureas or basal insulin.

JAMA Network: Asshociation of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes